Liquidia (NASDAQ:LQDA) Insider Sells 9,218 Shares of Company Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,218 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $262,528.64. Following the sale, the insider directly owned 126,368 shares in the company, valued at approximately $3,598,960.64. The trade was a 6.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The shares were sold at an average price of $76.84, for a total value of $2,269,392.56.
• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00.

Liquidia Trading Down 3.1%

Liquidia stock traded down $0.86 during mid-day trading on Tuesday, hitting $26.81. The company’s stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The firm has a market capitalization of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The stock’s fifty day moving average is $63.40 and its two-hundred day moving average is $61.76.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period last year, the business earned ($0.49) EPS. Liquidia’s revenue was up 1842.1% compared to the same quarter last year. On average, analysts anticipate that Liquidia Corporation will post 2.05 EPS for the current year.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LQDA. Stephens set a $130.00 price objective on Liquidia in a research report on Friday, July 24th. HC Wainwright decreased their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, October 2nd. Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Bank of America lifted their price target on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $83.69.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the company. WINTON GROUP Ltd purchased a new stake in shares of Liquidia in the 2nd quarter valued at $335,000. Arizona State Retirement System lifted its stake in Liquidia by 5.4% during the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after acquiring an additional 900 shares in the last quarter. Nykredit A S purchased a new position in shares of Liquidia in the second quarter valued at approximately $177,000. Corient Private Wealth LP acquired a new position in shares of Liquidia in the second quarter valued at approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Liquidia in the second quarter valued at approximately $1,236,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).